Literature DB >> 18281475

Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.

Peter Ouillette1, Harry Erba, Lisa Kujawski, Mark Kaminski, Kerby Shedden, Sami N Malek.   

Abstract

Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous illness with a variable clinical course. Loss of chromosomal material on chromosome 13 at cytoband 13q14 is the most frequent genetic abnormality in CLL, but the molecular aberrations underlying del13q14 in CLL remain incompletely characterized. We analyzed 171 CLL cases for loss of heterozygosity and subchromosomal copy loss on chromosome 13 in DNA from fluorescence-activated cell sorting-sorted CD19(+) cells and paired buccal cells using the Affymetrix XbaI 50k SNP array platform. The resulting high-resolution genomic maps, together with array-based measurements of expression levels of RNA in CLL cases with and without del13q14 and quantitative PCR-based expression analysis of selected genes, support the following conclusions: (a) del13q14 is heterogeneous and composed of multiple subtypes, with deletion of Rb or the miR15a/miR16 loci serving as anatomic landmarks, respectively; (b) del13q14 type Ia deletions are relatively uniform in length and extend from breakpoints close to the miR15a/miR16 cluster to a newly identified telomeric breakpoint cluster at the approximately 50.2 to 50.5 Mb physical position; (c) LATS2 RNA levels are approximately 2.6-fold to 2.8-fold lower in cases with del13q14 type I that do not delete Rb, as opposed to del13q14 type II or all other CLL cases; (d) PHLPP RNA is absent in approximately 50% of CLL cases with del13q14; and (e) approximately 15% of CLL cases display marked reductions in miR15a/miR16 expression that are often but not invariably associated with bi-allelic miR15a/miR16 loss. These data should aid future investigations into biological differences imparted on CLL by different del13q14 subtypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281475     DOI: 10.1158/0008-5472.CAN-07-3105

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  73 in total

1.  Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.

Authors:  Enrica Rampazzo; Laura Bonaldi; Livio Trentin; Carlo Visco; Sonia Keppel; Silvia Giunco; Federica Frezzato; Monica Facco; Elisabetta Novella; Ilaria Giaretta; Paola Del Bianco; Gianpietro Semenzato; Anita De Rossi
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

2.  The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.

Authors:  Claudia Nitsche; Mouad Edderkaoui; Ryan M Moore; Guido Eibl; Noriyuki Kasahara; Janet Treger; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Gastroenterology       Date:  2011-10-29       Impact factor: 22.682

3.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

4.  Chronic lymphocytic leukemia--genomics lead the way.

Authors:  Daniel Mertens; Lars Bullinger; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

5.  Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; Megan Hanna; Bethany Tesar; Lillian Werner; Nathalie Pochet; John M Asara; Yaoyu E Wang; Paola Dal Cin; Stacey M Fernandes; Christina Thompson; Laura Macconaill; Catherine J Wu; Yves Van de Peer; Mick Correll; Aviv Regev; Donna Neuberg; Arnold S Freedman
Journal:  Clin Cancer Res       Date:  2012-05-23       Impact factor: 12.531

Review 6.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

7.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

Review 8.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

9.  Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.

Authors:  Jane Houldsworth; Asha Guttapalli; Venkata Thodima; Xiao Jie Yan; Geetu Mendiratta; Tania Zielonka; Gouri Nanjangud; Weiyi Chen; Sujata Patil; Anthony Mato; Jennifer R Brown; Kanti Rai; Nicholas Chiorazzi; R S K Chaganti
Journal:  Leuk Lymphoma       Date:  2013-11-12

10.  The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study.

Authors:  Shuhua Yi; Heng Li; Zengjun Li; Wenjie Xiong; Huimin Liu; Wei Liu; Rui Lv; Zhen Yu; Dehui Zou; Yan Xu; Gang An; Lugui Qiu
Journal:  Int J Hematol       Date:  2017-04-24       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.